Completion of Acquisition or Disposition of Assets The information set forth in

Entry Into a Material Definitive Agreement. Closing of Share Purchase Agreement As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on January 14, 2026 (the “Prior 8-K”), on January 12, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into that certain Share Purchase Agreement (“Share Purchase Agreement”), by and among the Company, Lifeward Ltd. (“Lifeward”) and Oratech Pharma, Inc., the Company’s wholly-owned subsidiar…

Entry into a Material Definitive Agreement . On February 19, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into a Warrant Agreement (the “Warrant Agreement”) with Scilex Holding Company (“Scilex”). Pursuant to the Warrant Agreement, the Company deferred its right to receive an amortization payment scheduled to be paid by Scilex on October 1, 2025 as set forth in the amortization schedule included in that certain Senior Secured Convertible Note (the “Tranche B Notes”) issued to the…

Entry Into a Material Definitive Agreement. Share Purchase Agreement On January 12, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into that certain Share Purchase Agreement (“Share Purchase Agreement”), by and among the Company, Lifeward Ltd. (“Lifeward”) and Oratech Pharma, Inc., the Company’s wholly-owned subsidiary (“Oratech”). Pursuant to the Share Purchase Agreement, Lifeward agreed to acquire all of the outstanding equity interests in Oratech from the Company in consideratio…

Other Events. On January 13, 2026, the Company issued a press release announcing the Notes Private Placement and Share Purchase Transaction. A copy of the press release is attached as Exhibit 99.1 hereto.

Other Events. On January 7, 2026, Oramed Pharmaceuticals Inc. (the “Company”) issued a press release announcing it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Additionally, the press release announced that the Company’s Board of Directors has approved a cash dividend payment of $0.25 per share to re…

Director — Leonard Sank: A long-serving director (18 years) is resigning, which is a genuine departure from the board but not a loss of a C-suite executive.

Other Events. As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2025, on July 22, 2025, Oramed Pharmaceuticals Inc. (the “Company”) entered into an Option Agreement for the Repurchase of Warrants (the “Option Agreement”) with Scilex Holding Company (“Scilex”) pursuant to which, among other things, the Company granted to Scilex an option to repurchase warrants held by the Company to purchase an aggregate of 6,500,000 shares…

Material Modification to Rights of Security Holders. The information set forth in

of this Current Report on Form 8-K (including the financial information contained in Exhibit 99.1 attached hereto) is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Exchange Act or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such…

Entry into a Material Definitive Agreement. On November 16, 2025, the Board of Directors of Oramed Pharmaceuticals Inc. (the “Company”) declared a dividend of one common stock purchase right (a “Right”) for each outstanding share of common stock, par value $0.012 per share (the “Common Stock”), of the Company. The dividend is payable on November 27, 2025 to the stockholders of record at the close of business on November 27, 2025 (the “Record Date”). Each Right initially entitles the registere…

Termination of a Material Definitive Agreement As previously reported on Current Report on Form 8-K, on January 22, 2024, the Company and its wholly-owned subsidiary, Oramed Ltd., entered into a Joint Venture Agreement (the “JV Agreement”) with HTIT Biotech and Technowl Limited, a wholly-owned indirect subsidiary of HTIT Biotech (“HTIT Sub,” and together with HTIT Biotech, collectively “HTIT”), pursuant to which, subject to the terms and conditions set forth in the JV Agreement, the parties a…

Results of Operations and Financial Condition On October 23, 2025, the Company issued a letter to its shareholders (the “Shareholder Letter”), which contains certain unaudited, preliminary and estimated financial information of the Company as of September 30, 2025 (the “Financial Information”). Cautionary Statement Regarding the Financial Information The Company cautions investors and potential investors not to place undue reliance upon the Financial Information contained in the Shareholder L…

Entry Into a Material Definitive Agreement On October 20, 2025, Oramed Pharmaceuticals Inc. (the “Company”) entered into a share repurchase agreement (the “Repurchase Agreement”) with Hefei Tianhui Biotech Co., Ltd. (“HTIT Biotech”) pursuant to which HTIT Biotech agreed to sell back to the Company an aggregate of 1,155,367 shares of common stock, par value $0.012 per share of the Company (the “Shares”) to the Company at a purchase price of $2.23 per Share for an aggregate price of $2,576,468.…

Other Events. As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2025, on July 22, 2025, Oramed Pharmaceuticals Inc. (the “Company”) entered into an Option Agreement for the Repurchase of Warrants (the “Option Agreement”) with Scilex Holding Company (“Scilex”) pursuant to which, among other things, the Company granted to Scilex an option to repurchase warrants held by the Company to purchase an aggregate of 6,500,000 shares…

The filing discloses the approval of an amendment to a stock incentive plan, which is a compensatory arrangement rather than a change in management personnel.

Entry into a Material Definitive Agreement. Option Agreement for the Repurchase of Warrants As previously disclosed, on September 21, 2023, Oramed Pharmaceuticals Inc. (the “Company”) entered into and consummated the transactions contemplated by a Securities Purchase Agreement (as amended by that certain Amendment No.1 thereto, the “2023 SPA”) with Scilex Holding Company (“Scilex”) and Acquiom Agency Services LLC (the “Agent”). Pursuant to the 2023 SPA, Scilex issued to the Company (i) a Seni…

Other Events On May 21, 2025, Oramed Pharmaceuticals Inc. (the “Company”) announced that its Board of Directors authorized a one-year extension of the Company’s current stock buyback program, which was set to expire in June 2025, pursuant to which the Company may, from time to time, purchase up to $20,000,000 in maximum value of its common stock, of which, as of May 21, 2025, $2,494,000 in value of shares has been repurchased. The renewed stock buyback program (the “Stock Buy Back Program”) r…

Entry into a Material Definitive Agreement Securities Purchase Agreement On April 24, 2025, Oramed Ltd. (“ Oramed ”), a wholly-owned subsidiary of Oramed Pharmaceuticals Inc. (the “ Company ”) entered into that certain share purchase agreement (the “ Purchase Agreement ”) with Alpha Tau Medical Ltd. (“ Alpha Tau ”) for the purchase by Oramed of 14,110,121 (the “ Shares ”) of Alpha Tau’s ordinary shares, no par value per share (the “ Ordinary Shares ”), in a registered direct offering (the “ O…

Entry into a Material Definitive Agreement. Background As previously announced, on October 7, 2024, Oramed Pharmaceuticals Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Convertible Notes SPA ”) with certain institutional investors (such investors, the “ Tranche B Institutional Investors ” and together with the Company, the “ Tranche B Noteholders ”) and Scilex Holding Company (“ Scilex ”) , pursuant to which, among other things, the Tranche B Noteholders collectiv…

Entry into a Material Definitive Agreement. ZTlido Rest of World License Agreement As previously announced by the Company on October 8, 2024, the Company and certain other investors (together with the Company, the “ LidoDev Institutional Investors ”) entered into that certain Rest of World License Term Sheet (the “ ZTlido ROW Term Sheet ”) with Scilex Holding Company (“ Scilex ”), pursuant to which the parties agreed to negotiate in good faith additional agreements required to effectuate such…

and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing. Forward-Looking Statements This Current Report on Form 8-K, along wit…

Entry into a Material Definitive Agreement Ancillary Agreement Completion Protocol and Supplemental Agreement On February 7, 2025, Oramed Pharmaceuticals Inc. (the “ Company ”), Oramed NewCo, Inc. (“ Oramed NewCo ”), Oramed Ltd. (“ Oramed Ltd. ”), Hefei Tianhui Biotech Co., Ltd. (“ HTIT Biotech ”) and Technowl Limited (“ HTIT Sub ” and together with HTIT Biotech, collectively, “ HTIT ”) entered into that certain Ancillary Agreement Completion Protocol and Supplemental Agreement (the “ Supplem…

Entry into a Material Definitive Agreement Amendment to Senior Secured Promissory Note, dated as of January 21, 2025 As previously disclosed, on September 21, 2023, Oramed Pharmaceuticals Inc. (the “Company”) entered into and consummated the transactions contemplated by a Securities Purchase Agreement (the “Scilex SPA”) with Scilex Holding Company (“Scilex”) and Acquiom Agency Services LLC (the “Agent”). Pursuant to the Scilex SPA, in exchange for Scilex assuming certain outstanding obligatio…

Entry into a Material Definitive Agreement. Deferral and Consent under Tranche B Senior Secured Convertible Note As previously disclosed by Oramed Pharmaceuticals Inc. (the “ Company ”), Scilex Holding Company (“ Scilex ”) issued a Tranche B Senior Secured Convertible Note, dated as of October 8, 2024, to the Company and certain other investors, including Nomis Bay Ltd, BPY Limited and 3i, LP (together with the Company, the “ Tranche B Noteholders ”) in the aggregate principal amount of $50,0…